Research Reference
Peptide Half-Life Reference
Half-life is the time required for the measured concentration of a peptide to fall to half of its initial value under defined conditions. Reported values vary widely with assay, species, and matrix. The figures below summarize values reported in published preclinical and in-vitro literature for reference only.
Reported preclinical half-life values
| Peptide | Reported half-life range (preclinical) | Notes |
|---|---|---|
| BPC-157 | ~30–60 minutes (plasma, animal models) | Short circulating half-life despite stable structure |
| TB-500 (Thymosin β4 fragment) | ~2–3 hours (animal models) | Synthetic fragment of Thymosin β4 |
| CJC-1295 (no DAC) | ~30 minutes | Unmodified analog |
| CJC-1295 with DAC | ~6–8 days | Albumin-binding modification |
| Ipamorelin | ~2 hours | Selective GH secretagogue scaffold |
| Tesamorelin | ~25–40 minutes (plasma) | GHRH analog |
| Retatrutide | Reported multi-day half-life in published preclinical literature | Triple-agonist scaffold; confirm against current literature |
| GHK-Cu | Highly tissue-dependent | Bound to copper in active form |
How half-life is measured
Half-life is determined by sampling peptide concentration at defined intervals in a chosen matrix (plasma, serum, buffer, cell culture medium) and fitting the decay to a pharmacokinetic model. Values can differ by an order of magnitude between matrices and between species.
Why values vary
Reported half-lives depend on: enzymatic environment, species, route, dose, assay sensitivity, and whether the peptide is modified (e.g. PEGylated, lipidated, or DAC-bound). A peptide's half-life in plasma is not the same as its half-life in cell culture or tissue.
Frequently Asked Questions
What is the half-life of BPC-157?+
Published preclinical reports place the plasma half-life of BPC-157 at roughly 30–60 minutes in animal models, despite its structural stability. Values vary with assay and species.
What is the difference between CJC-1295 and CJC-1295 with DAC?+
The DAC (Drug Affinity Complex) modification binds the peptide to serum albumin, extending the reported preclinical half-life from approximately 30 minutes to roughly 6–8 days.
Why do reported half-lives differ between sources?+
Half-life depends on the matrix sampled, the species, the assay, and any structural modifications. A single peptide can have very different reported values in plasma vs cell culture.